https://www.selleckchem.com/sc....reening-libraries.ht
ignificant impact on treatment decisions and NCCN guideline adherence in HR-positive breast cancers. Although cases of stage IV disease in the first-line therapy setting were also more likely to be changed, the effect was not statistically significant (P = .22). Additional research on decision impact, patient-physician communication, learning, and clinical outcomes is needed to establish the overall value of the technology. Inefficiencies in the clinical trial infrastructure result in protracted trial completion timelines, physician-
Like
Comment
Share
